Department of Pathology, Sorbonne Université, Assistance Publique Hôpitaux de Paris, Hôpital Armand Trousseau, Paris, France.
Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Histopathology. 2022 May;80(6):928-945. doi: 10.1111/his.14634. Epub 2022 Mar 22.
Renal cell carcinomas (RCCs) represent 2-5% of kidney malignancies in children and adolescents. Appropriate diagnostic and classification are crucial for the correct management of the patients and in order to avoid inappropriate pre-operative chemotherapy, which is usually recommended if a Wilms' tumour is suspected.
A French-Italian series of 93 renal cell carcinomas collected from 1990 to 2019 in patients aged less than 18 years was reclassified according to the 2016 World Health Organization (WHO) classification and the latest literature. TFE3 and TFEB fluorescence in-situ hybridisation (FISH) analyses and a panel of immunohistochemical stains were applied. The median age at diagnosis was 11 years (range = 9 months-17 years). MiT family (MiTF) translocation RCCs accounted for 52% of the tumours, followed by papillary (20%) and unclassified RCCs (13%). Other subtypes, such as SDHB-deficient and fumarate hydratase-deficient RCCs, represented 1-3% of the cases. We also described a case of ALK-rearranged RCC with a metanephric adenoma-like morphology.
A precise histological diagnosis is mandatory, as targeted therapy could be applied for some RCC subtypes, i.e. MiTF-translocation and ALK-translocation RCC. Moreover, some RCC subtypes may be associated with a predisposition syndrome that will impact patients' and family's management and genetic counselling. A precise RCC subtype is also mandatory for the clinical management of the patients and inclusion in new prospective clinical trials.
肾细胞癌(RCC)占儿童和青少年肾脏恶性肿瘤的 2-5%。适当的诊断和分类对于正确管理患者至关重要,并且可以避免不必要的术前化疗,如果怀疑是 Wilms 瘤,则通常建议进行这种化疗。
对 1990 年至 2019 年期间年龄小于 18 岁的 93 例肾细胞癌患者的法国-意大利系列进行了重新分类,这些患者的分类依据是 2016 年世界卫生组织(WHO)分类和最新文献。应用 TFE3 和 TFEB 荧光原位杂交(FISH)分析以及一组免疫组织化学染色。诊断时的中位年龄为 11 岁(范围=9 个月-17 岁)。MiT 家族(MiTF)易位 RCC 占肿瘤的 52%,其次是乳头状(20%)和未分类 RCC(13%)。其他亚型,如 SDHB 缺陷型和富马酸水合酶缺陷型 RCC,占病例的 1-3%。我们还描述了一例具有间变型腺瘤样形态的 ALK 重排 RCC 病例。
必须进行精确的组织学诊断,因为某些 RCC 亚型,即 MiTF 易位和 ALK 易位 RCC,可以应用靶向治疗。此外,某些 RCC 亚型可能与易患综合征相关,这将影响患者及其家属的管理和遗传咨询。精确的 RCC 亚型对于患者的临床管理和纳入新的前瞻性临床试验也是必要的。